{"cursor":"9724","size":15,"audio":[],"currentlang":"en","article":"{{Drugbox\n| Verifiedfields = changed Watchedfields = changed verifiedrevid = 416459611\n| IUPAC_name = 3-(((6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-Î²-\n| D -mannopyranosyl)oxy)-methyl)-12(R)-[(6-deoxy-5-C-methyl-4-O-\n| (2-methyl-1-oxopropyl)-Î²- D-lyxo-hexopyranosyl)oxy]-11(S)-ethyl-\n| 8(S)-hydroxy-18(S)-(1(R)-hydroxyethyl)-9,13,15-trimethyloxacyclooctadeca-\n| 3,5,9,13,15-pentaene-2-one image = Lipiarmycin.png alt =\n\n\n| tradename = Dificid, Dificlir licence_US = Fidaxomicin pregnancy_AU =  pregnancy_US = B pregnancy_category = legal_AU =\n|  legal_CA =  legal_UK =  legal_US = Rx-only legal_status = routes_of_administration = Oral\n\n\n| bioavailability = protein_bound = metabolism = elimination_half-life = 11.7 Â±\n| 4.80 hours excretion = Feces (92%), urine (0.59%)\n\n\n| CAS_number_Ref = CAS_number = 873857-62-6 ATCvet = ATC_prefix = A07\n| ATC_suffix = AA12 PubChem = 11528171 ChEBI_Ref = ChEBI = 68590 DrugBank_Ref =\n| DrugBank = UNII_Ref = UNII = Z5N076G8YQ KEGG_Ref = KEGG = D09394 ChEMBL_Ref =\n| ChEMBL = 1255800\n\n\n| C=52 | H=74 | Cl=2 | O=18 molecular_weight = 1058.04 g/mol synonyms =\n| Clostomicin B1, lipiarmicin, lipiarmycin, lipiarmycin A3, OPT 80, PAR 01, PAR\n| 101, tiacumicin B\n}}\n\n'Fidaxomicin' (trade names 'Dificid', 'Dificlir', and previously OPT-80 and PAR-\n101) is the first in a new class of narrow spectrum macrocyclic antibiotic\ndrugs. It is a fermentation product obtained from the actinomycete\n[[Dactylosporangium]] aurantiacum subspecies hamdenesis. Optimer Pharmaceuticals, Inc.\n[http://www.dificid.com/upload/dificid.pdf Dificid, Full Prescribing\nInformation], NDA 201,699. 2011. Adis R&D Profiles [http://adisonline-\n.com/drugsrd/Fulltext/2010/10010/Fidaxomicin__Difimicin__Lipiarmycin__OPT_80_.5-\n.aspx Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.]\nDrugs in R & D (Open Access): 28 May 2010 - Volume 10 - Issue 1 - pp 37-\n45. Fidaxomicin is non-systemic, meaning it is minimally absorbed into the\nbloodstream, it is bactericidal, and it has demonstrated selective eradication\nof pathogenic [[Clostridium difficile]] with minimal disruption to the multiple\nspecies of bacteria that make up the normal, healthy intestinal flora. The\nmaintenance of normal physiological conditions in the colon can reduce the\nprobability of Clostridium difficile infection recurrence.\n\n\nIt is marketed by Optimer Pharmaceuticals for treatment of Clostridium difficile\ninfection. Fidaxomicin is available in a 200 mg tablet that is administered\nevery 12 hours for a recommended duration of 10 days. Total duration of therapy\nshould be determined by the patient's clinical status.\n","linknr":307,"url":"Lipiarmycin","recorded":1362500979,"links":20,"instances":[],"pdf":["http://www.dificid.com/upload/dificid.pdf"],"categories":["Macrolide antibiotics"],"headings":["Mechanism","Clinical trials","Approvals and indications","References"],"image":["//upload.wikimedia.org/wikipedia/commons/thumb/f/f8/Lipiarmycin.png/220px-Lipiarmycin.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","//bits.wikimedia.org/static-1.21wmf10/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.21wmf10/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[],"members":[],"related":["Macrocycle","Antibiotic","Bactericidal","Pathogenic","Bacteria","Intestinal_flora","RNA_polymerase","Gram_positive","Clostridia","Phase_III","Vancomycin","Vancomycin"]}